12/19
07:50 am
adap
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK [Yahoo! Finance]
Neutral
Report
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK [Yahoo! Finance]
12/2
04:07 pm
adap
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) [Yahoo! Finance]
Low
Report
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) [Yahoo! Finance]
11/27
12:48 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Mizuho from $3.00 to $1.50. They now have an "outperform" rating on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Mizuho from $3.00 to $1.50. They now have an "outperform" rating on the stock.
11/27
07:15 am
adap
Dr Crystal Mackall Confirmed to Keynote Immuno-Oncology 360º 2025
Low
Report
Dr Crystal Mackall Confirmed to Keynote Immuno-Oncology 360º 2025
11/22
08:21 am
adap
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
11/16
07:42 am
adap
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/15
02:08 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
11/15
12:02 am
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/14
02:38 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at HC Wainwright from $4.00 to $3.50. They now have a "buy" rating on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at HC Wainwright from $4.00 to $3.50. They now have a "buy" rating on the stock.
11/14
12:17 pm
adap
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [Yahoo! Finance]
Medium
Report
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [Yahoo! Finance]
11/14
02:31 am
adap
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [Yahoo! Finance]
High
Report
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [Yahoo! Finance]
11/13
04:22 pm
adap
Adaptimmune Reports Q3 2024 Financial and Business Updates [Yahoo! Finance]
High
Report
Adaptimmune Reports Q3 2024 Financial and Business Updates [Yahoo! Finance]
11/7
01:55 pm
adap
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio
Medium
Report
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio
11/5
09:31 am
adap
Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]
Medium
Report
Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]
10/10
02:44 pm
adap
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]
Low
Report
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]